<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935922</url>
  </required_header>
  <id_info>
    <org_study_id>200816799-1</org_study_id>
    <nct_id>NCT00935922</nct_id>
  </id_info>
  <brief_title>CCRC: Understanding the Effects of Omega-3 Fatty Acids Versus Lignans in Flaxseed on Metabolic and Inflammatory Markers Leading to Diabetes and Cardiovascular Disease</brief_title>
  <official_title>CCRC: Understanding the Effects of Omega-3 Fatty Acids vs. Lignans in Flaxseed on Metabolic and Inflammatory Markers Leading to Diabetes and Cardiovascular Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flax Canada 2015 Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of flaxseed on atherogenic lipids, plasma
      inflammatory markers, and insulin sensitivity.

      We hypothesize that flaxseed omega-3 fatty acids will improve the lipid profile (decrease
      triglyceride, total and LDL-cholesterol and increase HDL-cholesterol).

      Flaxseed is the richest dietary source of lignan secoisolariciresinol diglucoside (SDG).
      Lignans are estrogens found in plant sources that behave similar to endogenous estrogens and
      have been associated with cardiovascular benefits due to their antioxidant activity.
      Therefore, we also hypothesize that flax-lignans will cause a significant decrease in LDL
      oxidation and in inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6),
      IL-1B, serum fatty acid binding protein 4 (FABP-4), and serum amyloid attached to high
      density lipoprotein (HDL-SAA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved lipid profile</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Body Weight</condition>
  <condition>Lipids</condition>
  <condition>Blood Glucose</condition>
  <condition>Insulin</condition>
  <arm_group>
    <arm_group_label>Soybean oil bar</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A nutrition bar enriched with soybean oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flaxseed bar with low lignans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A nutrition bar enriched with flaxseed oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flaxseed bars with high lignans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A nutrition bar enriched with flaxseed oil and high lignans</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed</intervention_name>
    <description>Flaxseed omega-3 fatty acids and lignans</description>
    <arm_group_label>Soybean oil bar</arm_group_label>
    <arm_group_label>Flaxseed bar with low lignans</arm_group_label>
    <arm_group_label>Flaxseed bars with high lignans</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or postmenopausal women in the 40-65 years age range. Body Mass Index in the range
             of 25-39

        Exclusion Criteria:

          -  Women are are premenopausal

          -  Smoking

          -  Diabetes

          -  Cancer

          -  Gout

          -  Untreated thyroid disease

          -  Kidney Disease

          -  Liver Disease

          -  Use of lipid lowering drugs

          -  Use of insulin sensitizing drugs

          -  Use of ACE inhibitors or other blood pressure lowering medications

          -  Use of over the counter or prescription anti-obesity medications

          -  Weight loss of 10% or more within the last 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidika Kasim-Karakas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCRC</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Sidika E. Karakas, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Flaxseed</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Heart health</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

